Eradivir advances antibody-recruiting flu therapy into Phase 2
Eradivir has begun a Phase 2 study of EV25, testing a differentiated antiviral approach that recruits existing antibodies to infected cells and virus particles.
Most antiviral drugs try to block viral replication directly. Eradivir is testing a different mechanism: recruit the body’s existing antibodies to the infection.
What happened
Eradivir dosed the first patient in a Phase 2 study of EV25 in adults with naturally occurring influenza infection in Bangladesh.
The randomised, double-blind study compares three EV25 dose levels with placebo and oseltamivir.
EV25 is designed to recruit existing circulating antibodies to infected cells and virus particles rather than directly blocking viral replication.
Why it matters
This is a concrete clinical-development milestone rather than a preclinical announcement.
The differentiated thesis is that an antibody-recruiting mechanism could potentially remain useful later in infection than conventional antivirals that inhibit replication directly.
But that remains to be tested. The Phase 2 study still needs to establish safety and efficacy in naturally infected patients.
The bigger picture
Antiviral innovation is expanding beyond conventional replication blockers.
Biotech companies are exploring ways to redirect existing immune mechanisms toward pathogens. Eradivir’s trial is an early test of whether that concept can translate into clinically meaningful treatment.